针对T细胞耗尽:非小细胞肺癌的新兴策略
Xianqiang Liu1,2, Xiaowei Xi3, Shengshan Xu1
1Department of Thoracic Surgery, Jiangmen Central Hospital, Jiangmen, Guangdong, China.
Frontiers in immunology
|December 27, 2024
概括
T细胞耗尽会影响非小细胞肺癌 (NSCLC) 的免疫治疗. 本综述探讨了其原因和扭转疲劳的策略,旨在改善肺癌治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症研究 癌症研究
背景情况:
- 肺癌仍然是全球癌症死亡的主要原因之一.
- 针对T细胞功能的免疫疗法显示出希望,但面临挑战.
- 由于瘤微环境刺激而导致的功能障碍状态的T细胞耗尽,限制了治疗的有效性.
研究的目的:
- 审查推动非小细胞肺癌 (NSCLC) 中T细胞耗尽的分子机制.
- 评估用于逆转T细胞枯竭的新兴策略.
- 探索这些见解如何提高NSCLC免疫疗法的临床疗效.
主要方法:
- 对T细胞耗尽驱动因素的当前知识的综合.
- 对T细胞耗尽逆转策略的临床前和临床研究的评估.
- 来自报告的临床试验和研究数据的整合.
主要成果:
- T细胞耗尽是有效NSCLC免疫疗法的重要障碍.
- 一些新的策略正在出现,以克服T细胞疲劳.
- 了解疲劳机制是改善免疫治疗反应率的关键.
结论:
- 逆转T细胞枯竭具有显著的潜力,可以改善NSCLC患者的治疗结果.
- 需要进一步的研究和治疗开发来将这些发现转化为临床实践.
- 本综述为未来的肺癌免疫疗法研究提供了路线图.
相关概念视频
Tumor Immunotherapy
397
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
397
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K


